<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487654</url>
  </required_header>
  <id_info>
    <org_study_id>13SM0713</org_study_id>
    <nct_id>NCT02487654</nct_id>
  </id_info>
  <brief_title>Ectopy Triggering Ganglionated Plexus Ablation to Prevent Atrial Fibrillation</brief_title>
  <acronym>GANGLIA-AF</acronym>
  <official_title>Ectopy Triggering Ganglionated Plexus Ablation to Prevent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a common heart rhythm disorder which can significantly affect a&#xD;
      patient's quality of life and cause strokes. Abnormal electrical activity from the pulmonary&#xD;
      veins are thought to be the most common cause of this condition. Current ablative strategy in&#xD;
      drug refractory AF is pulmonary vein isolation (PVI), where the pulmonary veins are&#xD;
      electrically isolated from the body of the left atrium. However, success rate of this&#xD;
      procedure remain ~50-70% for a single procedure despite advances in mapping and ablation&#xD;
      techniques.&#xD;
&#xD;
      Ganglionated plexuses (GP) are dense clusters of nerves in the atria that are implicated in&#xD;
      AF. Endocardial high frequency stimulation (HFS) delivered within the local atrial refractory&#xD;
      period can trigger ectopy and AF from specific GP sites (ET-GP). The aim of this study was to&#xD;
      understand the role of ET-GP ablation in the treatment of AF by comparing two different&#xD;
      strategies:&#xD;
&#xD;
        1. Pulmonary vein isolation alone&#xD;
&#xD;
        2. GP ablation alone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-centre study recruiting patients with paroxysmal AF indicated&#xD;
      for AF ablation.&#xD;
&#xD;
      180 patients will be recruited. Patients are randomised to either GP ablation alone or to&#xD;
      PVI. All antiarrhythmics are stopped for at least 48 hours prior to their procedures.&#xD;
&#xD;
      All have general anaesthesia and CARTO system (Biosense Webster, inc.) are used for 3D&#xD;
      electroanatomical mapping of the left atrium.&#xD;
&#xD;
      Patients randomised to GP ablation will have high frequency mapping performed within the&#xD;
      atrial refractory period to identify ectopy or AF triggering GP (ET-GP) sites in the left&#xD;
      atrium. Patients in this group will only have GP ablation and will not have pulmonary veins&#xD;
      isolated.&#xD;
&#xD;
      The primary endpoint is any documented atrial arrhythmia 30 seconds or more after a 3 month&#xD;
      blanking period. This will be assessed for up to 12 months post-procedure, using 48hr Holter&#xD;
      monitors at 3, 6, 9 and 12 month intervals.&#xD;
&#xD;
      Secondary endpoints include mortality, major complications and redo procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documented recurrent atrial arrhythmia lasting 30 seconds or more after a blanking period of 3 months.</measure>
    <time_frame>3 to 12 months post-ablation.</time_frame>
    <description>Outcome measure will be assessed up to 12 months of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major complications, mortality and redo procedures</measure>
    <time_frame>3 to 12 months post-ablation.</time_frame>
    <description>Major complications include significant bleed requiring transfusions, pericardiocentesis, stroke.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganglionated plexus ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <description>Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.</description>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <other_name>PVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ganglionated plexus ablation</intervention_name>
    <description>Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium</description>
    <arm_group_label>Ganglionated plexus ablation</arm_group_label>
    <other_name>GP ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females eighteen (18) to eighty five (85) years old&#xD;
&#xD;
          -  Paroxysmal atrial fibrillation&#xD;
&#xD;
          -  Suitable candidate for catheter ablation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to catheter ablation&#xD;
&#xD;
          -  Presence of a cardiac thrombus&#xD;
&#xD;
          -  valvular disease that is grade moderate or greater&#xD;
&#xD;
          -  Any form of cardiomyopathy&#xD;
&#xD;
          -  On amiodarone therapy&#xD;
&#xD;
          -  Severe cerebrovascular disease&#xD;
&#xD;
          -  Active gastrointestinal bleeding&#xD;
&#xD;
          -  Renal failure (on dialysis or at risk of requiring dialysis)&#xD;
&#xD;
          -  Active infection or fever&#xD;
&#xD;
          -  Life expectancy shorter than the duration of the trial&#xD;
&#xD;
          -  Allergy to contrast&#xD;
&#xD;
          -  Intractable heart failure (NYHA Class IV)&#xD;
&#xD;
          -  Bleeding or clotting disorders or inability to receive heparin&#xD;
&#xD;
          -  Serum Creatinine &gt;200umol/L&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c ≥73mmol/mol or HbA1c ≤64mmol/mol and Fasting Blood&#xD;
             Glucose ≥9.2mmol/L)&#xD;
&#xD;
          -  Malignancy needing therapy&#xD;
&#xD;
          -  Pregnancy or women of childbearing potential not using a highly effective method of&#xD;
             contraception&#xD;
&#xD;
          -  Patients in current research or have recently been involved in any research prior to&#xD;
             recruitment will not be included in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prapa Kanagaratnam, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College NHS Healthcare Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal atrial fibrillation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Ganglionated plexus</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Pulmonary vein ectopy</keyword>
  <keyword>High frequency stimulation</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>Ganglionated plexi</keyword>
  <keyword>atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

